Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Growing human antibodies in algae

16.01.2003


Inexpensive and fast route to large-scale production, say scientists at The Scripps Research Institute



A group of scientists at The Scripps Research Institute (TSRI) have used algae to express an antibody that targets herpes virus, describing the work in an upcoming issue of the journal Proceedings of the National Academy of Sciences.

This antibody could potentially be an ingredient in an anti-herpes topical cream or other anti-herpes treatments, but more importantly the algae expression technology that the TSRI team used could facilitate production of any number of human antibodies and other proteins on a massive scale.


"This is a fast, new, effective way to make human therapeutic proteins," says TSRI Associate Professor Stephen P. Mayfield, Ph.D., who conducted the research with Research Associate Scott E. Franklin, Ph.D., and TSRI President Richard A. Lerner, M.D.

Significantly, the researchers were able to produce the antibody at a much lower cost than has been achieved in the past. In fact, they say they can now make antibodies, soluble receptors, and other proteins so much more cheaply that an entire new class of therapeutics may become accessible.

"You can’t make [a drug] if the time and expense is such that you have to sell that drug for hundreds of thousands of dollars," says Mayfield. "This has to be the way we make drugs in the future."

From Pond Scum to Pharmacy Shelf

Also called immunoglobulins, antibodies are proteins produced by immune cells that are designed to recognize a wide range of foreign pathogens. After a bacterium, virus, or other pathogen enters the bloodstream, antibodies target antigens--proteins, carbohydrate molecules, and other pieces of the pathogen--specific to that foreign invader. These antibodies then alert the immune system to the presence of the invaders and attract lethal "effector" immune cells to the site of infection.

Antibodies can also be useful as therapeutics for a number of human diseases ranging from rheumatoid arthritis to leukemia. Likewise, there are many other human proteins that could potentially be used as drugs.

In fact, there may be over 200 proteins that could potentially be new anti-cancer, anti-inflammatory, anti-arthritis compounds, says Mayfield. As an example, an anti-IgE antibody, termed Omalizumab, has already shown great efficacy in human clinical trials for the treatment of allergic rhinitis and asthma. Unfortunately, the costs of producing the antibody, coupled with the relatively small amounts which can be produced with current technologies, has severely limited its availability.

In cases where scientists want to make an abundance of proteins, they often turn to the simplest expression system--bacteria. However, this does not work for large, complicated proteins like antibodies because bacteria do not have the machinery to assemble them into the correct structure. So large proteins are usually produced through an expensive and complicated process involving the fermentation of mammalian cells.

Algae may offer a cheaper and easier way to produce the proteins. Since algae grow naturally and use carbon dioxide from the air as a carbon source and sunlight as an energy source, whole ponds--tens of thousands of liters--of the algae can be grown once they are modified to produce the protein of interest.

"The scale on which you can grow these algae is enormous," notes Franklin.

Modifying the algae to produce proteins entails inserting a gene into the genome of the chloroplast, the organelles within the alga cell that converts sunlight and carbon dioxide into plant matter. The algae then express and assemble the antibodies within the chloroplasts, which can later be purified, intact.

Now that the researchers have established the fundamental technology, they are looking at applying it to any number of proteins and receptors.

"We think we can now put in pretty much any gene that we want and have it express," says Mayfield.

The article, "Expression and assembly of a fully active antibody in algae," authored by Stephen P. Mayfield, Scott E. Franklin, and Richard A. Lerner, is available online at: http://www.pnas.org/cgi/content/abstract/0237108100v1, and will be published in the journal Proceedings of the National Academy of Sciences on January 21, 2003.


This work was supported by funds from Sea Grant, the National Institutes of Health, and Syngenta Corporation.

Jason Bardi | EurekAlert!
Further information:
http://www.scripps.edu/

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>